405 Million Deal Expected To Enhance Patient Access To Cancer Treatments

Pharmacosmos Group to Acquire G1 Therapeutics

$405 Million Deal Expected to Enhance Patient Access to Cancer Treatments

Copenhagen, Denmark and Research Triangle Park, NC – August 7, 2024

Pharmacosmos AS, a leading Danish pharmaceutical company, has entered into an agreement to acquire G1 Therapeutics Inc., a clinical-stage oncology company headquartered in Research Triangle Park, North Carolina. The transaction, valued at approximately $405 million, is expected to close in the fourth quarter of 2024, subject to customary closing conditions.

The acquisition will combine Pharmacosmos' strong commercial capabilities and global reach with G1 Therapeutics' innovative oncology pipeline. G1 Therapeutics' lead product, Cosela (trilaciclib), is a first-in-class CDK4/6 inhibitor that is approved for the treatment of patients with extensive-stage small cell lung cancer. Cosela has demonstrated promising clinical activity and tolerability, with the potential to improve outcomes for patients with this aggressive form of cancer.

In addition to Cosela, G1 Therapeutics has a pipeline of early-stage oncology assets, including several novel therapeutic candidates. These assets complement Pharmacosmos' existing portfolio of cancer treatments and provide the combined company with a robust platform for future growth.

"We are excited to announce the acquisition of G1 Therapeutics," said Søren Tulstrup, CEO of Pharmacosmos. "This transaction will strengthen our oncology portfolio and expand our global reach. We believe that Cosela has the potential to become a leading treatment option for patients with extensive-stage small cell lung cancer, and we are confident that we can leverage our expertise to maximize its commercial potential."

"We are proud to join forces with Pharmacosmos," said Mark Velleca, CEO of G1 Therapeutics. "Pharmacosmos' strong commercial infrastructure and global reach will enable us to bring Cosela to more patients worldwide. We believe that this combination will create a powerful player in the oncology market and accelerate the development of our pipeline of innovative cancer treatments."

Upon completion of the transaction, G1 Therapeutics will become a wholly owned subsidiary of Pharmacosmos. The combined company will have a global presence with operations in Denmark, the United States, and other countries. The transaction is expected to be accretive to Pharmacosmos' earnings per share in 2025.